🧾 What This Document Is 📣

This is an 8-K filing, which means Provectus is filing a report to announce a material, unscheduled event to the public. The core announcement is that the company has chosen a new location for its operations and where it will host its annual meeting. 👉 This signals a significant, planned transition for the company, making the new location and its history very important to investors.

🏢 What Provectus Does 🔬

Provectus Biopharmaceuticals is a clinical-stage biotechnology company. It is primarily focused on developing and advancing immunotherapy medicines. The foundation of its research is a first-in-class synthetic small molecule called rose bengal sodium, which belongs to the halogenated xanthene family.

• Therapeutic Focus: The company's current clinical programs are structured across several critical areas:
  • Oncology (cancer treatment)
  • Dermatology (skin conditions)
  • Ophthalmology (eye care)
• Pipeline Depth: Beyond these main areas, Provectus is also conducting proof-of-concept programs in several other fields, including hematology, wound healing, infectious diseases, and tissue repair. 👉 This broad pipeline suggests Provectus aims to make its rose bengal sodium molecule a versatile treatment platform, rather than being limited to one disease.

📅 2026 Annual Meeting Details 🗓️

The filing announces the official details for the upcoming 2026 Annual Meeting of Stockholders. This is when the company's owners (the stockholders) gather to discuss corporate governance and elect directors.

• Date and Time: The meeting is scheduled for Thursday, June 18, 2026, starting at 4:00 p.m. Eastern Time.
• Location: Critically, the meeting will be held at the Perkins Place Office Building, located at 525 Portland Street, Knoxville, Tennessee 37919.
• Why it Matters: Holding the Annual Meeting at Perkins Place—which the company plans to make its permanent headquarters—symbolizes and solidifies the company's commitment to this new location.

🏡 Moving to Perkins Place 📍

Provectus is undertaking a major physical move and intends to relocate its corporate offices. The move is from its current location at 800 S. Gay Street, Suite 1610 (First Horizon Plaza Tower) to the new, dedicated facility at Perkins Place.

• The Transition: The Company plans to formally transition from its current offices in the First Horizon Plaza Tower to Perkins Place sometime in 2026.
• Operational Advantage: The move is viewed as a strategic necessity that will allow Provectus to better manage costs as it continues to grow and add resources.

✨ Perkins Place's History and Potential 🏰

Perkins Place is more than just a new office; it is a historic and strategically valuable asset. The location and history underline the scale of the company’s future plans.

• Historical Significance: Opened in 1927 as Perkins Elementary School, the building was renamed in honor of Angie Villette Warren Perkins, who was significant in the early history of the Knoxville Board of Education.
• Physical Scope: The property is a fully renovated structure covering 22,941 square feet on a campus spanning 3.23 acres, and it includes ample parking.
• Future Flexibility: The property includes additional land and flexible zoning. This provides "optionality" (flexibility) for future facility development, including space dedicated specifically to research, operations, and logistics. 👉 This ability to build out different specialized functions on the same campus is a major advantage for a growing biotech firm.

💡 Management's Strategic Outlook 🔮

Provectus’s Chairman and CEO, Ed Pershing, provided commentary that ties the physical move to the company’s larger business ambition. He framed the move not just as a change of address, but as a strategic commitment to the future.

• The Vision: Mr. Pershing stated, “Holding our 2026 Annual Meeting of Stockholders at Perkins Place is the right setting for this moment... Provectus’s proprietary synthetic small molecule Rose Bengal Sodium is a molecule being systematically recognized and developed across oncology, dermatology, ophthalmology, and beyond. Perkins Place was not a new building when PYA first claimed it. In both cases, the value was already there. The work was to see it, commit to it, and build.”
• What this means: By linking the building's history of value recognition with Provectus's own development of its molecule, management is emphasizing that their success is rooted in identifying and building upon existing, valuable opportunities.

📈 Operational Benefits and Growth Strategy 🚀

The move to Perkins Place is generating specific benefits beyond just having a new address. It underpins the company's long-term growth model.

• Cost Management: The relocation is expected to provide Provectus with a clear pathway to "effectively manage costs as it grows and adds resources."
• Long-Term Stability: The initial arrangement secured the headquarters for Provectus while providing the East Tennessee Foundation with a minority ownership interest and a long-term headquarters, suggesting a stable, sustained presence in the community.

👥 Key Investor Logistics and Contacts 📝

This section outlines essential operational details for stockholders and interested investors regarding the legal nature of the filing and how to access necessary documents.

• Proxy Filing Note: This press release is not a proxy statement or a solicitation. Stockholders are heavily urged to read the Preliminary Proxy Statement and the Definitive Proxy Statement (when available) for complete information regarding the 2026 Annual Meeting proposals.
• Document Access: Stockholders can obtain free copies of the preliminary proxy statement and other SEC filings by accessing the SEC’s home page or by writing a request to Provectus Biopharmaceuticals, Inc., Attn: Secretary, 800 S Gay St, Suite 1610, Knoxville, Tennessee 37929.
• Contact Information:
  • CFO: Heather Raines, CPA at [email protected] (866) 594-5999
  • Investor Relations & Media: Susan Xu at [email protected] (778) 323-0959

🧠 The Analogy 🏗️

Think of Provectus’s move like a successful architect moving from a small, rented apartment to building their own specialized, historic headquarters. They aren't just moving walls; they are acquiring a whole campus with extra land and history. This new, permanent home gives them the physical breathing room and specialized workshop space they need to build revolutionary products (their therapies) without worrying about running out of room or facing unpredictable costs.

🧩 Final Takeaway 🔑

The core message is that Provectus is entering a new, highly valuable chapter in Knoxville, using its historic headquarters (Perkins Place) as a symbol of its long-term stability, operational flexibility, and sustained commitment to developing its advanced immunotherapy platform.